Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | EPOR | P19235 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | EBP | Q15125 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774560 | 1.00 | MEN1 (0.63) | MEN1KMT2AIDO1PAMKDM4E | |
| SCHEMBL2106139 | 0.89 | MEN1 (0.54) | MEN1KMT2AIDO1PAMKDM4E | |
| SCHEMBL3301329 | 0.87 | MEN1 (0.61) | MEN1KMT2AIDO1PAMKDM4E | |
| SCHEMBL3037072 | 0.87 | MEN1 (0.61) | MEN1KMT2AIDO1PAMKDM4E | |
| SCHEMBL8989760 | 0.85 | MEN1 (0.54) | MEN1KMT2AKDM4EHTR2ANR1I2 | |
| SCHEMBL7076295 | 0.85 | MEN1 (0.54) | MEN1KMT2AKDM4EHTR2ANR1I2 | |
| SCHEMBL1931712 | 0.85 | MEN1 (0.54) | MEN1KMT2AIDO1PAMKDM4E | |
| SCHEMBL1931710 | 0.85 | MEN1 (0.54) | MEN1KMT2AIDO1PAMKDM4E | |
| SCHEMBL3299271 | 0.83 | MEN1 (0.62) | MEN1KMT2AKDM4EHTR2ANR1I2 | |
| SCHEMBL17707693 | 0.83 | MEN1 (0.57) | MEN1KMT2AIDO1PAMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1967509-B1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7652170-B2 | Method for producing primary amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090287023-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1967509-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20070155636-A1 | Lubricating oil additive and lubricating oil composition containing the same | ADEKA CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1717298-A1 | LUBRICATING OIL ADDITIVE AND LUBRICATING OIL COMPOSITION CONTAINING SAME | Adeka Corporation (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090287023-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | HRH3, HRH4, C5 | MEN1 404/4885KMT2A 1415/4885IDO1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.